Nevro (NVRO) Competitors $4.05 -0.10 (-2.41%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NVRO vs. SMLR, SIBN, KIDS, TMCI, CLPT, NNOX, TCMD, DCTH, ZIMV, and NPCEShould you be buying Nevro stock or one of its competitors? The main competitors of Nevro include Semler Scientific (SMLR), SI-BONE (SIBN), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), ClearPoint Neuro (CLPT), Nano-X Imaging (NNOX), Tactile Systems Technology (TCMD), Delcath Systems (DCTH), ZimVie (ZIMV), and NeuroPace (NPCE). These companies are all part of the "medical equipment" industry. Nevro vs. Semler Scientific SI-BONE OrthoPediatrics Treace Medical Concepts ClearPoint Neuro Nano-X Imaging Tactile Systems Technology Delcath Systems ZimVie NeuroPace Nevro (NYSE:NVRO) and Semler Scientific (NASDAQ:SMLR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking. Do insiders & institutionals have more ownership in NVRO or SMLR? 95.5% of Nevro shares are owned by institutional investors. Comparatively, 49.4% of Semler Scientific shares are owned by institutional investors. 3.2% of Nevro shares are owned by insiders. Comparatively, 30.2% of Semler Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer NVRO or SMLR? Nevro presently has a consensus target price of $8.05, indicating a potential upside of 98.77%. Given Nevro's higher possible upside, analysts clearly believe Nevro is more favorable than Semler Scientific.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nevro 3 Sell rating(s) 11 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.79Semler Scientific 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Does the MarketBeat Community believe in NVRO or SMLR? Nevro received 502 more outperform votes than Semler Scientific when rated by MarketBeat users. Likewise, 63.19% of users gave Nevro an outperform vote while only 50.00% of users gave Semler Scientific an outperform vote. CompanyUnderperformOutperformNevroOutperform Votes50363.19% Underperform Votes29336.81% Semler ScientificOutperform Votes150.00% Underperform Votes150.00% Which has better valuation & earnings, NVRO or SMLR? Semler Scientific has lower revenue, but higher earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNevro$419.15M0.36-$92.21M-$1.89-2.14Semler Scientific$58.94M10.51$20.58M$2.0536.45 Is NVRO or SMLR more profitable? Semler Scientific has a net margin of 27.00% compared to Nevro's net margin of -16.54%. Semler Scientific's return on equity of 20.31% beat Nevro's return on equity.Company Net Margins Return on Equity Return on Assets Nevro-16.54% -23.52% -10.83% Semler Scientific 27.00%20.31%18.78% Does the media refer more to NVRO or SMLR? In the previous week, Semler Scientific had 1 more articles in the media than Nevro. MarketBeat recorded 9 mentions for Semler Scientific and 8 mentions for Nevro. Semler Scientific's average media sentiment score of 0.57 beat Nevro's score of 0.10 indicating that Semler Scientific is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nevro 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Semler Scientific 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, NVRO or SMLR? Nevro has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. SummarySemler Scientific beats Nevro on 13 of the 18 factors compared between the two stocks. Ad Huge AlertsUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Click here to see how this opportunity could transform your portfolio. Get Nevro News Delivered to You Automatically Sign up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVRO vs. The Competition Export to ExcelMetricNevroSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$151.76M$4.41B$5.14B$19.67BDividend YieldN/A44.87%4.81%3.51%P/E Ratio-2.1424.95135.1943.74Price / Sales0.3646.561,224.5917.60Price / CashN/A44.2040.6521.73Price / Book0.507.254.885.46Net Income-$92.21M$13.83M$118.97M$987.68M7 Day Performance-6.03%-2.91%15.53%-2.33%1 Month Performance-5.59%3.03%15.54%0.63%1 Year Performance-81.42%47.13%34.63%16.39% Nevro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVRONevro2.2613 of 5 stars$4.05-2.4%$8.05+98.8%-81.3%$151.76M$419.15M-2.141,215SMLRSemler Scientific1.4323 of 5 stars$73.98+10.1%N/A+65.1%$613.29M$68.18M35.2792News CoverageGap UpHigh Trading VolumeSIBNSI-BONE4.4532 of 5 stars$13.85+3.2%$23.00+66.1%-27.2%$580.87M$138.89M-14.59350Positive NewsKIDSOrthoPediatrics4.107 of 5 stars$22.49+1.7%$40.00+77.9%-27.9%$544.71M$148.73M-17.98200Positive NewsTMCITreace Medical Concepts1.069 of 5 stars$7.53+0.4%$7.40-1.7%-28.7%$469.12M$187.12M-7.58250Analyst ForecastCLPTClearPoint Neuro0.5163 of 5 stars$16.37+6.8%$11.33-30.8%+162.3%$451.57M$30.43M-22.21110Positive NewsNNOXNano-X Imaging2.1245 of 5 stars$7.47+8.4%$12.00+60.6%+7.7%$431.61M$10.68M-8.79190Positive NewsTCMDTactile Systems Technology3.6624 of 5 stars$17.77-0.8%$23.00+29.4%+26.1%$426.48M$274.42M27.57980DCTHDelcath Systems2.44 of 5 stars$12.56+3.7%$21.50+71.2%+274.3%$401.59M$22.64M-9.6776Gap DownHigh Trading VolumeZIMVZimVie3.2562 of 5 stars$13.80+0.5%$18.33+32.9%+24.3%$380.88M$457.43M-1.052,600News CoveragePositive NewsNPCENeuroPace3.8505 of 5 stars$11.10+0.6%$14.60+31.5%+27.2%$331.31M$76.45M-11.03170Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies Semler Scientific Competitors SI-BONE Competitors OrthoPediatrics Competitors Treace Medical Concepts Competitors ClearPoint Neuro Competitors Nano-X Imaging Competitors Tactile Systems Technology Competitors Delcath Systems Competitors ZimVie Competitors NeuroPace Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NVRO) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nevro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
